Date: 2013-10-22
Type of information: Production agreement
Compound: undisclosed Roche\'s commercial biologic medicines
Company: Roche (Switzerland) Samsung Biologics (South Korea)
Therapeutic area: undisclosed
Type agreement: manufacturing
production
Action mechanism:
Disease:
Details: * On October 22, 2013, Samsung BioLogics has announced that Samsung BioLogics and Roche have entered into a long term strategic manufacturing agreement under which Samsung will manufacture Roche\'s proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, of which one is currently under construction. Terms of the agreement will not be disclosed, including financial terms and products to be manufactured.
Financial terms:
Latest news:
